Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
Study looks at factor VIII products for hemophilia A
The odds of inhibitory antibody development were the same for children with hemophilia A who took plasma-derived factor VIII products and those in the recombinant group, a Dutch study found. Researchers reported in the New England Journal of Medicine that inhibitor development risk was not linked with the von Willebrand factor content of these products or with switching between plasma-derived and recombinant.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .